Background: The effects of high-dose folic acid (FA) supplementation in healthy individuals on blood folate concentrations and immune response are unknown.Objective: The aim of the study was to evaluate the effects of daily consumption of a tablet containing 5 mg FA on serum folate; number and cytotoxicity of natural killer (NK) cells; mRNA expression of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR), interferon γ (IFNG), tumor necrosis factor α (TNFA), and interleukin 8 (IL8) genes; and concentrations of serum inflammatory markers. Methods: This prospective clinical trial was conducted in 30 healthy Brazilian adults (15 women), aged 27.7 y (95% CI: 26.4, 29.1 y), with a body mass index (in kg/m2) of 23.1 (95% CI: 22.0, 24.3). Blood was collected at baseline and after 45 and 90 d of the intervention. Serum folate concentrations were measured by microbiological assay and HPLC-tandem mass spectrometry [folate forms, including unmetabolized folic acid (UMFA)]. We used real-time polymerase chain reaction to assess mononuclear leukocyte mRNA expression and flow cytometry to measure the number and cytotoxicity of NK cells. Results: Serum folate concentrations increased by ∼5-fold after the intervention (P < 0.001), and UMFA concentrations increased by 11.9- and 5.9-fold at 45 and 90 d, respectively, when compared with baseline (P < 0.001). UMFA concentrations increased (>1.12 nmol/L) in 29 (96.6%) participants at day 45 and in 26 (86.7%) participants at day 90. We observed significant reductions in the number (P < 0.001) and cytotoxicity (P = 0.003) of NK cells after 45 and 90 d. Compared with baseline, DHFR mRNA expression was higher at 90 d (P = 0.006) and IL8 and TNFA mRNA expressions were higher at 45 and 90 d (P = 0.001 for both). Conclusion: This noncontrolled intervention showed that healthy adults responded to a high-dose FA supplement with increased UMFA concentrations, changes in cytokine mRNA expression, and reduced number and cytotoxicity of NK cells. This trial was registered at www.ensaiosclinicos.gov.br as RBR-2pr7zp.
Background: The effects of high-dose folic acid (FA) supplementation in healthy individuals on blood folate concentrations and immune response are unknown.Objective: The aim of the study was to evaluate the effects of daily consumption of a tablet containing 5 mg FA on serum folate; number and cytotoxicity of natural killer (NK) cells; mRNA expression of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR), interferon γ (IFNG), tumor necrosis factor α (TNFA), and interleukin 8 (IL8) genes; and concentrations of serum inflammatory markers. Methods: This prospective clinical trial was conducted in 30 healthy Brazilian adults (15 women), aged 27.7 y (95% CI: 26.4, 29.1 y), with a body mass index (in kg/m2) of 23.1 (95% CI: 22.0, 24.3). Blood was collected at baseline and after 45 and 90 d of the intervention. Serum folate concentrations were measured by microbiological assay and HPLC-tandem mass spectrometry [folate forms, including unmetabolized folic acid (UMFA)]. We used real-time polymerase chain reaction to assess mononuclear leukocyte mRNA expression and flow cytometry to measure the number and cytotoxicity of NK cells. Results: Serum folate concentrations increased by ∼5-fold after the intervention (P < 0.001), and UMFA concentrations increased by 11.9- and 5.9-fold at 45 and 90 d, respectively, when compared with baseline (P < 0.001). UMFA concentrations increased (>1.12 nmol/L) in 29 (96.6%) participants at day 45 and in 26 (86.7%) participants at day 90. We observed significant reductions in the number (P < 0.001) and cytotoxicity (P = 0.003) of NK cells after 45 and 90 d. Compared with baseline, DHFR mRNA expression was higher at 90 d (P = 0.006) and IL8 and TNFA mRNA expressions were higher at 45 and 90 d (P = 0.001 for both). Conclusion: This noncontrolled intervention showed that healthy adults responded to a high-dose FA supplement with increased UMFA concentrations, changes in cytokine mRNA expression, and reduced number and cytotoxicity of NK cells. This trial was registered at www.ensaiosclinicos.gov.br as RBR-2pr7zp.
Authors: Emily C McGowan; Xiumei Hong; Jacob Selhub; Ligi Paul; Robert A Wood; Elizabeth C Matsui; Corinne A Keet; Xiaobin Wang Journal: J Allergy Clin Immunol Pract Date: 2019-06-25
Authors: Padma Maruvada; Patrick J Stover; Joel B Mason; Regan L Bailey; Cindy D Davis; Martha S Field; Richard H Finnell; Cutberto Garza; Ralph Green; Jean-Louis Gueant; Paul F Jacques; David M Klurfeld; Yvonne Lamers; Amanda J MacFarlane; Joshua W Miller; Anne M Molloy; Deborah L O'Connor; Christine M Pfeiffer; Nancy A Potischman; Joseph V Rodricks; Irwin H Rosenberg; Sharon A Ross; Barry Shane; Jacob Selhub; Sally P Stabler; Jacquetta Trasler; Sedigheh Yamini; Giovanna Zappalà Journal: Am J Clin Nutr Date: 2020-11-11 Impact factor: 7.045
Authors: Dieuwertje E Kok; Ciara H O'Flanagan; Michael F Coleman; Zahra Ashkavand; Stephen D Hursting; Sergey A Krupenko Journal: Biochimie Date: 2020-04-15 Impact factor: 4.079
Authors: Manuela A Orjuela; Fabiola Mejia-Rodriguez; Amado D Quezada; Tania G Sanchez-Pimienta; Teresa Shamah-Levy; Josefina Romero-Rendón; Silvia Bhatt-Carreño; M Verónica Ponce-Castañeda; Maria A Castro; Ligi Paul; Salvador Villalpando Journal: Am J Clin Nutr Date: 2019-12-01 Impact factor: 7.045
Authors: Mohammed Iddir; Alex Brito; Giulia Dingeo; Sofia Sosa Fernandez Del Campo; Hanen Samouda; Michael R La Frano; Torsten Bohn Journal: Nutrients Date: 2020-05-27 Impact factor: 5.717